Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 179

1.

Design, synthesis and anti-tuberculosis activity of 1-adamantyl-3-heteroaryl ureas with improved in vitro pharmacokinetic properties.

North EJ, Scherman MS, Bruhn DF, Scarborough JS, Maddox MM, Jones V, Grzegorzewicz A, Yang L, Hess T, Morisseau C, Jackson M, McNeil MR, Lee RE.

Bioorg Med Chem. 2013 May 1;21(9):2587-99. doi: 10.1016/j.bmc.2013.02.028. Epub 2013 Feb 26.

2.

The structure-activity relationship of urea derivatives as anti-tuberculosis agents.

Brown JR, North EJ, Hurdle JG, Morisseau C, Scarborough JS, Sun D, Korduláková J, Scherman MS, Jones V, Grzegorzewicz A, Crew RM, Jackson M, McNeil MR, Lee RE.

Bioorg Med Chem. 2011 Sep 15;19(18):5585-95. doi: 10.1016/j.bmc.2011.07.034. Epub 2011 Jul 24.

3.
4.

Screening a library of 1600 adamantyl ureas for anti-Mycobacterium tuberculosis activity in vitro and for better physical chemical properties for bioavailability.

Scherman MS, North EJ, Jones V, Hess TN, Grzegorzewicz AE, Kasagami T, Kim IH, Merzlikin O, Lenaerts AJ, Lee RE, Jackson M, Morisseau C, McNeil MR.

Bioorg Med Chem. 2012 May 15;20(10):3255-62. doi: 10.1016/j.bmc.2012.03.058. Epub 2012 Mar 31.

5.

1,3-Disubstituted and 1,3,3-trisubstituted adamantyl-ureas with isoxazole as soluble epoxide hydrolase inhibitors.

Burmistrov V, Morisseau C, Danilov D, Harris TR, Dalinger I, Vatsadze I, Shkineva T, Butov GM, Hammock BD.

Bioorg Med Chem Lett. 2015 Dec 1;25(23):5514-9. doi: 10.1016/j.bmcl.2015.10.066. Epub 2015 Oct 23.

6.

Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents.

Pieroni M, Wan B, Cho S, Franzblau SG, Costantino G.

Eur J Med Chem. 2014 Jan 24;72:26-34. doi: 10.1016/j.ejmech.2013.11.007. Epub 2013 Nov 13.

PMID:
24333612
7.

Peptidyl-urea based inhibitors of soluble epoxide hydrolases.

Morisseau C, Newman JW, Tsai HJ, Baecker PA, Hammock BD.

Bioorg Med Chem Lett. 2006 Oct 15;16(20):5439-44.

8.

Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs.

Tsai HJ, Hwang SH, Morisseau C, Yang J, Jones PD, Kasagami T, Kim IH, Hammock BD.

Eur J Pharm Sci. 2010 Jun 14;40(3):222-38. doi: 10.1016/j.ejps.2010.03.018. Epub 2010 Mar 30.

9.

Synthesis and antitubercular evaluation of 4-carbonyl piperazine substituted 1,3-benzothiazin-4-one derivatives.

Peng CT, Gao C, Wang NY, You XY, Zhang LD, Zhu YX, Xv Y, Zuo WQ, Ran K, Deng HX, Lei Q, Xiao KJ, Yu LT.

Bioorg Med Chem Lett. 2015 Apr 1;25(7):1373-6. doi: 10.1016/j.bmcl.2015.02.061. Epub 2015 Mar 2.

PMID:
25754492
10.

Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility.

Kim IH, Heirtzler FR, Morisseau C, Nishi K, Tsai HJ, Hammock BD.

J Med Chem. 2005 May 19;48(10):3621-9.

11.

Unsymmetrical non-adamantyl N,N'-diaryl urea and amide inhibitors of soluble expoxide hydrolase.

Anandan SK, Webb HK, Do ZN, Gless RD.

Bioorg Med Chem Lett. 2009 Aug 1;19(15):4259-63. doi: 10.1016/j.bmcl.2009.05.102. Epub 2009 May 30.

PMID:
19520575
12.
13.

Biologically active ester derivatives as potent inhibitors of the soluble epoxide hydrolase.

Kim IH, Nishi K, Kasagami T, Morisseau C, Liu JY, Tsai HJ, Hammock BD.

Bioorg Med Chem Lett. 2012 Sep 15;22(18):5889-92. doi: 10.1016/j.bmcl.2012.07.074. Epub 2012 Aug 2.

14.

2,3-dideoxy hex-2-enopyranosid-4-uloses as promising new anti-tubercular agents: design, synthesis, biological evaluation and SAR studies.

Saquib M, Husain I, Sharma S, Yadav G, Singh VK, Sharma SK, Shah P, Siddiqi MI, Kumar B, Lal J, Jain GK, Srivastava BS, Srivastava R, Shaw AK.

Eur J Med Chem. 2011 Jun;46(6):2217-23. doi: 10.1016/j.ejmech.2011.03.002. Epub 2011 Mar 8.

PMID:
21440336
15.

Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. a potent and selective series for further drug development.

Lilienkampf A, Pieroni M, Wan B, Wang Y, Franzblau SG, Kozikowski AP.

J Med Chem. 2010 Jan 28;53(2):678-88. doi: 10.1021/jm901273n.

PMID:
20000577
16.

5-Arylaminouracil Derivatives: New Inhibitors of Mycobacterium tuberculosis.

Matyugina E, Novikov M, Babkov D, Ozerov A, Chernousova L, Andreevskaya S, Smirnova T, Karpenko I, Chizhov A, Murthu P, Lutz S, Kochetkov S, Seley-Radtke KL, Khandazhinskaya AL.

Chem Biol Drug Des. 2015 Dec;86(6):1387-96. doi: 10.1111/cbdd.12603. Epub 2015 Jul 14. Erratum in: Chem Biol Drug Des. 2016 Feb;87(2):312.

PMID:
26061192
17.

Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.

Lilienkampf A, Mao J, Wan B, Wang Y, Franzblau SG, Kozikowski AP.

J Med Chem. 2009 Apr 9;52(7):2109-18. doi: 10.1021/jm900003c.

PMID:
19271749
18.
19.

Design, synthesis of benzocoumarin-pyrimidine hybrids as novel class of antitubercular agents, their DNA cleavage and X-ray studies.

Reddy DS, Hosamani KM, Devarajegowda HC.

Eur J Med Chem. 2015 Aug 28;101:705-15. doi: 10.1016/j.ejmech.2015.06.056. Epub 2015 Jul 16.

PMID:
26210508
20.

Structure-activity relationships of substituted oxyoxalamides as inhibitors of the human soluble epoxide hydrolase.

Kim IH, Lee IH, Nishiwaki H, Hammock BD, Nishi K.

Bioorg Med Chem. 2014 Feb 1;22(3):1163-75. doi: 10.1016/j.bmc.2013.12.027. Epub 2014 Jan 3.

Supplemental Content

Support Center